Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $216.19

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned an average recommendation of “Moderate Buy” from the eighteen analysts that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $220.12.

ALNY has been the subject of a number of research reports. HC Wainwright lifted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Chardan Capital reissued a “buy” rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Needham & Company LLC reissued a “buy” rating and set a $200.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, May 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th.

Alnylam Pharmaceuticals Trading Up 5.3 %

ALNY stock opened at $165.70 on Wednesday. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $218.88. The company has a market capitalization of $20.96 billion, a P/E ratio of -61.83 and a beta of 0.30. The firm has a 50 day simple moving average of $150.49 and a 200-day simple moving average of $162.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.40) EPS. On average, research analysts predict that Alnylam Pharmaceuticals will post -3.77 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.50% of the stock is owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Harbor Capital Advisors Inc. lifted its stake in Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 51 shares in the last quarter. EP Wealth Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 71 shares in the last quarter. Commerce Bank lifted its stake in Alnylam Pharmaceuticals by 1.7% during the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock valued at $896,000 after buying an additional 77 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 7.0% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 89 shares during the period. Finally, Metis Global Partners LLC increased its holdings in shares of Alnylam Pharmaceuticals by 2.2% in the 4th quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock valued at $839,000 after purchasing an additional 94 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.